These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17468668)

  • 1. Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program.
    Tossonian HK; Raffa JD; Grebely J; Trotter B; Viljoen M; Mead A; Khara M; McLean M; Duncan F; Fraser C; DeVlaming S; Conway B
    J Acquir Immune Defic Syndr; 2007 Jul; 45(3):324-7. PubMed ID: 17468668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.
    Andersson LM; Vesterbacka J; Blaxhult A; Flamholc L; Nilsson S; Ormaasen V; Sönnerborg A; Gisslén M
    Scand J Infect Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23294034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups.
    Lucas GM; Mullen BA; Weidle PJ; Hader S; McCaul ME; Moore RD
    Clin Infect Dis; 2006 Jun; 42(11):1628-35. PubMed ID: 16652321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Directly observed therapy for the management of HIV-infected patients in a methadone program.
    Conway B; Prasad J; Reynolds R; Farley J; Jones M; Jutha S; Smith N; Mead A; DeVlaming S
    Clin Infect Dis; 2004 Jun; 38 Suppl 5():S402-8. PubMed ID: 15156430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
    AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.
    Bonora S; Nicastri E; Calcagno A; Gonzalez de Requena D; D'Ettorre G; Sarmati L; Palmisano L; Vullo V; Di Perri G; Andreoni M
    J Med Virol; 2009 Mar; 81(3):400-5. PubMed ID: 19152404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.
    Altice FL; Friedland GH; Cooney EL
    AIDS; 1999 May; 13(8):957-62. PubMed ID: 10371177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.
    Gleason RL; Caulk AW; Seifu D; Rosebush JC; Shapiro AM; Schwartz MH; Eckard AR; Amogne W; Abebe W
    J Biomech; 2016 Sep; 49(13):2584-2592. PubMed ID: 27270208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Directly observed antiretroviral therapy for injection drug users with HIV infection.
    Clarke S; Keenan E; Ryan M; Barry M; Mulcahy F
    AIDS Read; 2002 Jul; 12(7):305-7, 312-6. PubMed ID: 12161852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
    AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
    Slish J; Ma Q; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Forrest A; Brazeau D; Boston NS; Catanzaro L; DiFrancesco R; Morse GD
    Ther Drug Monit; 2007 Oct; 29(5):560-5. PubMed ID: 17898644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
    Edén A; Andersson LM; Andersson O; Flamholc L; Josephson F; Nilsson S; Ormaasen V; Svedhem V; Säll C; Sönnerborg A; Tunbäck P; Gisslén M
    AIDS Res Hum Retroviruses; 2010 May; 26(5):533-40. PubMed ID: 20455766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
    Mallolas J; Podzamczer D; Milinkovic A; Domingo P; Clotet B; Ribera E; Gutiérrez F; Knobel H; Cosin J; Ferrer E; Arranz JA; Roca V; Vidal F; Murillas J; Pich J; Pedrol E; Llibre JM; Dalmau D; García I; Aranda M; Cruceta A; Martínez E; Blanco JL; Lazzari Ed; Gatell JM;
    J Acquir Immune Defic Syndr; 2009 May; 51(1):29-36. PubMed ID: 19390327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.
    Otero MJ; Fuertes A; Sánchez R; Luna G
    AIDS; 1999 May; 13(8):1004-5. PubMed ID: 10371190
    [No Abstract]   [Full Text] [Related]  

  • 17. Modified directly observed therapy (MDOT) for injection drug users with HIV disease.
    McCance-Katz EF; Gourevitch MN; Arnsten J; Sarlo J; Rainey P; Jatlow P
    Am J Addict; 2002; 11(4):271-8. PubMed ID: 12584870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy for drug users.
    Clarke SM; Mulcahy FM
    Int J STD AIDS; 2000 Oct; 11(10):627-31. PubMed ID: 11057932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy.
    Lucas GM; Mullen BA; McCaul ME; Weidle PJ; Hader S; Moore RD
    AIDS Patient Care STDS; 2007 Aug; 21(8):564-74. PubMed ID: 17711381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.